KR20230110563A - 항체 매개 거부 반응의 치료 방법 - Google Patents

항체 매개 거부 반응의 치료 방법 Download PDF

Info

Publication number
KR20230110563A
KR20230110563A KR1020237020679A KR20237020679A KR20230110563A KR 20230110563 A KR20230110563 A KR 20230110563A KR 1020237020679 A KR1020237020679 A KR 1020237020679A KR 20237020679 A KR20237020679 A KR 20237020679A KR 20230110563 A KR20230110563 A KR 20230110563A
Authority
KR
South Korea
Prior art keywords
inh
dose
administered
recipient
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237020679A
Other languages
English (en)
Korean (ko)
Inventor
존 로버츠
마르크 우크니스
크리스틴 보이트
Original Assignee
체에스엘 베링 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 체에스엘 베링 게엠베하 filed Critical 체에스엘 베링 게엠베하
Publication of KR20230110563A publication Critical patent/KR20230110563A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020237020679A 2020-11-20 2021-11-18 항체 매개 거부 반응의 치료 방법 Pending KR20230110563A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063116405P 2020-11-20 2020-11-20
US63/116,405 2020-11-20
PCT/US2021/059872 WO2022109124A1 (en) 2020-11-20 2021-11-18 Method for treating antibody-mediated rejection

Publications (1)

Publication Number Publication Date
KR20230110563A true KR20230110563A (ko) 2023-07-24

Family

ID=78918649

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237020679A Pending KR20230110563A (ko) 2020-11-20 2021-11-18 항체 매개 거부 반응의 치료 방법

Country Status (8)

Country Link
US (1) US20240000908A1 (https=)
EP (1) EP4247416A1 (https=)
JP (1) JP2023551193A (https=)
KR (1) KR20230110563A (https=)
CN (1) CN116568327A (https=)
AU (1) AU2021381360A1 (https=)
CA (1) CA3198740A1 (https=)
WO (1) WO2022109124A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025067383A1 (zh) * 2023-09-28 2025-04-03 荣昌生物制药(烟台)股份有限公司 用TACI-Fc融合蛋白治疗抗体介导性排斥反应的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3228502A1 (de) 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung des c1-inaktivators und seine verwendung
DE4222534A1 (de) 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
DE4244735A1 (de) 1992-08-24 1994-03-31 Behringwerke Ag Verwendung von C1-Inaktivator zur Bekämpfung von Komplikationen bei der Anwendung von Zytokinen, endogenen Mediatoren, gentechnisch produzierten Mediator-Hybriden oder Wachstumsfaktoren im Rahmen der therapeutischen Anwendung dieser Substanzen
DE69534265T2 (de) 1994-12-12 2006-05-04 Beth Israel Deaconess Medical Center, Inc., Boston Chimäre zytokine und ihre verwendung
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7053176B1 (en) 1999-09-16 2006-05-30 Altana Pharma Ag Combination of C1-INH and lung surfactant for the treatment of respiratory disorders
AU2003210806A1 (en) 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
PL2298347T3 (pl) 2003-05-06 2016-03-31 Bioverativ Therapeutics Inc Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
DK1641823T3 (da) 2003-06-12 2011-12-12 Lilly Co Eli GLP-1-analog fusionsproteiner
RU2370276C2 (ru) 2003-12-31 2009-10-20 Мерк Патент Гмбх Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ
PL2380587T3 (pl) 2005-12-21 2018-03-30 Pharming Intellectual Property B.V. Zastosowanie inhibitora C1 do zapobiegania uszkodzeniu niedokrwiennoreperfuzyjnemu
CA2678001C (en) 2007-02-12 2017-07-11 Stefan Schulte Therapeutic application of kazal-type serine protease inhibitors
EP4162947A1 (en) 2013-11-22 2023-04-12 Takeda Pharmaceutical Company Limited Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
US20160130324A1 (en) 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
US20190175683A1 (en) * 2016-08-05 2019-06-13 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor

Also Published As

Publication number Publication date
JP2023551193A (ja) 2023-12-07
AU2021381360A1 (en) 2023-06-22
CN116568327A (zh) 2023-08-08
EP4247416A1 (en) 2023-09-27
WO2022109124A1 (en) 2022-05-27
CA3198740A1 (en) 2022-05-27
US20240000908A1 (en) 2024-01-04

Similar Documents

Publication Publication Date Title
CA2644020C (en) Prolongation of survival of an allograft by inhibiting complement activity
JP6620206B2 (ja) 臓器移植患者における抗体媒介性拒絶反応のｃ１−エステラーゼ阻害剤を使用した治療方法
JP5590624B2 (ja) 補体活性を阻害することによる同種移植片の生存の延長
KR20230110563A (ko) 항체 매개 거부 반응의 치료 방법
EP0776217A1 (en) A method of treating a patient with a biologically active compound
Habal et al. Renal allografting in the patient with juvenile diabetes mellitus
HK40008415B (en) Treatment of antibody-mediated rejection in organ transplant patients with c1- esterase inhibitor
HK1240072A1 (en) Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
HK1101962B (en) Prolongation of survival of an allograft by inhibiting complement activity
AU2013200641A1 (en) Prolongation of survival of an allograft by inhibiting complement activity

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230619

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241114

Comment text: Request for Examination of Application